These therapeutic effects were associated with the induction of CD8+ T cell infiltration in the tumor, and reactivation and restoration of CD8+ T cell functions by blocking of PD-1/PD-L1 signaling (Figure 5). The gene discussed is CD8A; the disease is neoplasm.